Response to first salvage therapy in patients with relapse after SCT
| . | Total . | B-lineage . | T-lineage . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| n . | CR . | P . | n . | CR . | P . | n . | CR . | P . | |
| 48 . | 11 (23%)* . | 24 . | 6 (25%)* . | 24 . | 5 (21%)* . | ||||
| FLAG-IDA | 14 | 4 (29%) | > .05 | 10 | 4 (40%) | > .05 | 4 | 0 | > .05 |
| Induction | 10 | 4 (40%) | 6 | 2 | 4 | 2 | |||
| CLAEG | 3 | 0 | 3 | 0 | |||||
| Nelarabine | 8 | 3 | 8 | 3 | |||||
| HDAC ± Mitox | 1 | 0 | 1 | 0 | |||||
| Other | 9 | 0 | 8 | 0 | 1 | 0 | |||
| 2nd SCT in relapse† | 3 | 0 | 3 | 0 | |||||
| . | Total . | B-lineage . | T-lineage . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| n . | CR . | P . | n . | CR . | P . | n . | CR . | P . | |
| 48 . | 11 (23%)* . | 24 . | 6 (25%)* . | 24 . | 5 (21%)* . | ||||
| FLAG-IDA | 14 | 4 (29%) | > .05 | 10 | 4 (40%) | > .05 | 4 | 0 | > .05 |
| Induction | 10 | 4 (40%) | 6 | 2 | 4 | 2 | |||
| CLAEG | 3 | 0 | 3 | 0 | |||||
| Nelarabine | 8 | 3 | 8 | 3 | |||||
| HDAC ± Mitox | 1 | 0 | 1 | 0 | |||||
| Other | 9 | 0 | 8 | 0 | 1 | 0 | |||
| 2nd SCT in relapse† | 3 | 0 | 3 | 0 | |||||
Patients with evaluable information about the type of salvage therapy, without CNS involvement and with Ph/BCR-ABL–negative ALL.
HDAC indicates high-dose cytarabine; and Mitox, mitoxantrone.
No percentage was calculated in subgroups with total number of cases less than 10.
Patient received SCT as their first salvage treatment; and CR rate indicates the remission rate after SCT.